Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gary W. Middleton"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionB cells, which have long been thought to be minor players in the development of anti-tumor responses, have been implicated as key players in lung cancer pathogenesis and response to checkpoint blockade in patients with lung cancer. Enrich
Externí odkaz:
https://doaj.org/article/aace951dd8ed4f99849368e6815456c9
Autor:
Akshay J. Patel, Zena N. Willsmore, Naeem Khan, Alex Richter, Babu Naidu, Mark T. Drayson, Sophie Papa, Andrew Cope, Sophia N. Karagiannis, Esperanza Perucha, Gary W. Middleton
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Immune checkpoint blockade is a promising approach to treat lung cancer, however, immune related adverse events hold back success in some patients. Here authors show that regulatory B cells fail to limit self-reactive T cells in these patients, and B
Externí odkaz:
https://doaj.org/article/c2085253ca8c457fb16c85cb9930af88
Autor:
Akshay J Patel, Gary W Middleton
Publikováno v:
Immunotherapy Advances.
Summary In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small ce
Autor:
Gary W. Middleton, Justin Guinney, Benjamin E. Willcox, Philippe Taniere, Andrew D. Beggs, Mike J. Mason, Oliver Pickles, Ghaleb Goussous, Brian S. White, Neeraj Lal
Immunohistochemistry algorithms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a316ce60a4f96ed7166f598f44890ad6
https://doi.org/10.1158/1078-0432.22462406.v1
https://doi.org/10.1158/1078-0432.22462406.v1
Autor:
Gary W. Middleton, Justin Guinney, Benjamin E. Willcox, Philippe Taniere, Andrew D. Beggs, Mike J. Mason, Oliver Pickles, Ghaleb Goussous, Brian S. White, Neeraj Lal
Supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009ef75671cdedc66da206b3dd102658
https://doi.org/10.1158/1078-0432.22462376.v1
https://doi.org/10.1158/1078-0432.22462376.v1
Autor:
Gary W. Middleton, Justin Guinney, Benjamin E. Willcox, Philippe Taniere, Andrew D. Beggs, Mike J. Mason, Oliver Pickles, Ghaleb Goussous, Brian S. White, Neeraj Lal
Purpose: KRAS mutation is a common canonical mutation in colorectal cancer, found at differing frequencies in all consensus molecular subtypes (CMS). The independent immunobiological impacts of RAS mutation and CMS are unknown. Thus, we explored the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a282e1cb502188917ef91fe9a53cb6e
https://doi.org/10.1158/1078-0432.c.6525092
https://doi.org/10.1158/1078-0432.c.6525092
Publikováno v:
Cancer Research. 83:5943-5943
Background: Post-operative recurrence in lung cancer continues to pose a major clinical challenge. B cell and plasma cell presence has been shown to correlate with improved survival and lower relapse rates in solid cancers and with improved response
Autor:
Oliver J. Pickles, Kasun Wanigasooriya, Anetta Ptasinska, Akshay J. Patel, Helen L. Robbins, Claire Bryer, Celina M. Whalley, Louise Tee, Neeraj Lal, Maria Pinna, Nahla Elzefzafy, Phillipe Taniere, Andrew D. Beggs, Gary W. Middleton
Publikováno v:
Cancer Research. 83:2989-2989
Introduction: Tumor specific MHC class II (tsMHC-II) expression impacts tumor microenvironmental immunity. tsMHC-II positive cancer cells act as surrogate antigen presenting cells and targets for CD4+ T cell-mediated lysis. In colorectal cancer (CRC)
Autor:
Akshay J. Patel, Zena N. Willsmore, Naeem Khan, Alex Richter, Babu Naidu, Mark T. Drayson, Sophie Papa, Andrew Cope, Sophia N. Karagiannis, Esperanza Perucha, Gary W. Middleton
Publikováno v:
Nature communications. 13(1)
Checkpoint blockade with Pembrolizumab, has demonstrated durable clinical responses in advanced non-small cell lung cancer, however, treatment is offset by the development of high-grade immune related adverse events (irAEs) in some patients. Here, we
Autor:
Andrew D, Beggs, Mark P, Dilworth, Enric, Domingo, Rachel, Midgley, David, Kerr, Ian P M, Tomlinson, Gary W, Middleton
Publikováno v:
Oncoscience
Introduction BRAF mutant colorectal cancer carries a poor prognosis which is thought to be related to poor response to conventional chemotherapy. BRAF mutation is associated with the serrated tumour phenotype. We hypothesised that one of the mechanis